Shire wants out of that $172M Baxalta deal with CTI Bio
A few weeks after Seattle-based CTI Biopharma’s $CTIC troubled myelofibrosis drug pacritinib turned in some mixed late-stage data, Shire is preparing to punt its interest in the therapy.
Pacritinib was put on a full clinical hold by the FDA earlier in the year after investigators determined that patients in the drug arm were dying at a faster pace than the control group. That helped sink the biotech’s stock, which is now firmly entrenched in penny stock territory. The stock closed at 36 cents today.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.